Self-resolution of Epstein-Barr virus–associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate

Waldman, Mark A.; Callen, Jeffrey P.

doi:10.1016/j.jaad.2004.03.020

Cited by 44 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…61 One case of self-resolving EBV-associated B cell lymphoma of the brain occurred in a DM patient treated with methotrexate, MMF, and prednisone, which resolved with discontinuation of methotrexate and MMF. 140 In addition, there has been a report of Kaposi sarcoma in a patient with pemphigus vulgaris on combined immunosuppression with prednisone and MMF. 141 With prolonged high-dose immunosuppression, the risk of both nonmelanoma skin cancer and internal malignancy are increased.…”

Section: Malignancy Potentialmentioning

confidence: 99%

Mycophenolate mofetil in dermatology

Orvis

Wesson

Breza

et al. 2009

Journal of the American Academy of Dermatology

114

106

View full text Add to dashboard Cite

Section: Malignancy Potentialmentioning

confidence: 99%

Mycophenolate mofetil in dermatology

Orvis

Wesson

Breza

et al. 2009

Journal of the American Academy of Dermatology

114

106

View full text Add to dashboard Cite

“…Two small series of seven (four DM, three PM) and six (three PM, two DM, one overlap) patients, respectively, with refractory myositis experienced increased muscle strength and decreased serum CK levels along with a reduction in daily corticosteroid requirements with MMF [15,16]. The development of Bcell lymphoma of the central nervous system in a few patients remains a concern regarding use of MMF [17,18].…”

Section: Intravenous Immunoglobulinmentioning

confidence: 99%

Therapeutic Approaches in Myositis

Aggarwal

Oddis

2011

Curr Rheumatol Rep

View full text Add to dashboard Cite

The inflammatory myopathies are a heterogeneous group of diseases including dermatomyositis, polymyositis, and inclusion body myositis. Few clinical trials have been conducted in myositis, making it difficult to provide clear recommendations on the treatment of these rare disorders. Although corticosteroids have not been tested in randomized controlled trials, the general expert consensus confirms their first-line use. However, in many patients, corticosteroid toxicity leads to significant disability, or these agents are ineffective, which then requires additional immunosuppression. Intravenous immunoglobulin is a reasonable short-term treatment with proven benefit in a controlled trial, but its long-term effectiveness remains unknown. The evidence for other immunosuppressive therapies has been derived mainly from case reports and open studies. These agents include methotrexate and/or azathioprine, followed by cyclosporine or tacrolimus (particularly for antisynthetase antibody-positive patients) and mycophenolate mofetil (for refractory rash). Newer therapies (eg, rituximab) are encouraging, but results from the largest randomized controlled trial studying this agent are soon to follow. The balance of evidence suggests that immunosuppressive drugs are effective in dermatomyositis and polymyositis, although randomized controlled trials are lacking.

show abstract

“…Patients receiving methotrexate (MTX) are prone to lymphomas and other lymphoproliferative disorders (LPD) including polymorphic lymphoid proliferation (1,2). This phenomenon has been called MTX-associated lymphoproliferative disorder (MTX-LPD) and is categorised by WHO under "iatrogenic immunodeficiencyassociated LPD" (3).…”

Section: Short Communicationmentioning

confidence: 99%